2,632 results match your criteria prasugrel

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y receptor between selatogrel and oral P2Y antagonists.

CPT Pharmacometrics Syst Pharmacol 2021 May 6. Epub 2021 May 6.

Idorsia Pharmaceuticals Ltd, Clinical Pharmacology, Allschwil, Switzerland.

Selatogrel is a potent and reversible P2Y receptor antagonist developed for subcutaneous self-administration by patients with suspected acute myocardial infarction. After single-dose emergency treatment with selatogrel, patients are switched to long-term treatment with oral P2Y receptor antagonists. Selatogrel shows rapid onset and offset of inhibition of platelet aggregation (IPA) to overcome the critical initial time after acute myocardial infarction. Read More

View Article and Full-Text PDF

Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke.

J Clin Med 2021 Apr 29;10(9). Epub 2021 Apr 29.

Department of Cardiosciences, U.O.C. of Cardiology, Azienda Ospedaliera San Camillo-Forlanini, 00152 Roma, Italy.

Patients with coronary artery disease (CAD) and prior cerebrovascular events (CVE) are frequently faced in clinical practice and present a high rate of both ischemic and bleeding events. For these reasons, the antithrombotic management is particularly challenging in this subgroup of patients. Recent trials suggest that, although a potent antiplatelet strategy is safe in the acute phases of myocardial ischemia for these patients, the risk of major bleeding complications, including intracranial hemorrhage, is extremely high when the antithrombotic therapy is prolonged for a long period of time. Read More

View Article and Full-Text PDF

Comparative Effectiveness and Safety of Prasugrel versus Ticagrelor following Percutaneous Coronary Intervention: An Observational Study.

Pharmacotherapy 2021 May 1. Epub 2021 May 1.

College of Pharmacy, University of Rhode Island, Kingston, Rhode Island.

Background: Observational studies comparing ticagrelor and prasugrel in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) have yielded contradictory results, but these studies often did not consider differential censoring (e.g., for treatment switching or insurance disenrollment) or confounding by time-dependent factors. Read More

View Article and Full-Text PDF

De-escalation of prasugrel results in higher percentage of patients within optimal range of platelet reactivity.

Thromb Haemost 2021 Apr 30. Epub 2021 Apr 30.

Internal Medicine, Seoul National University Hospital, Seoul, Korea (the Republic of).

No Abstract. Read More

View Article and Full-Text PDF

Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.

JAMA 2021 Apr;325(15):1545-1555

Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas.

Importance: Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in the United States with an annual incidence of approximately 1 million. Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) reduces cardiovascular event rates after ACS.

Observations: In 2016, the updated guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) recommended aspirin plus a P2Y12 inhibitor for at least 12 months for patients with ACS. Read More

View Article and Full-Text PDF

Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial.

J Atheroscler Thromb 2021 Apr 16. Epub 2021 Apr 16.

Deutsches Herzzentrum München, Cardiology, and Technische Universität München.

Aim: Sex-specific analyses of direct head-to-head comparisons between newer P2Y inhibitors are limited. This study was conducted to assess the efficacy and safety of ticagrelor versus prasugrel in women and men with acute coronary syndromes (ACS) planned for an invasive strategy.

Methods: This pre-specified analysis of the ISAR-REACT 5 trial included 956 women and 3,062 men with ACS randomly assigned to either ticagrelor or prasugrel. Read More

View Article and Full-Text PDF

Not-high before-treatment platelet reactivity in patients with STEMI: prevalence, clinical characteristics, response to therapy and outcomes.

Platelets 2021 Apr 15:1-8. Epub 2021 Apr 15.

Cardiology Clinic, Sassari University Hospital, Sassari, Italy.

Platelet reactivity (PR) has been indicated as a pathophysiological key element for ST-Elevation Myocardial Infarction (STEMI) development. Patients with not-high before-treatment platelet reactivity (NHPR) have been poorly studied so far. The aim of this study is to investigate the prevalence, clinical characteristics, response to therapy and outcomes of baseline prior to treatment NHPR among patients with STEMI undergoing primary PCI. Read More

View Article and Full-Text PDF

Ticagrelor Utilization in Patients With Non-ST Elevation Acute Coronary Syndromes in Romania.

Am J Ther 2021 Apr 8. Epub 2021 Apr 8.

University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania; and University & Emergency Hospital, Bucharest, Romania.

Background: Dual antiplatelet therapy (DAPT) represents a major tool of non-ST elevation acute coronary syndrome (NSTE-ACS) management. The real-world usage of potent P2Y12 inhibitors within DAPT in middle-income countries is poorly described.

Study Question: To assess the factors that influence P2Y12 inhibitor choice at discharge in invasively managed NSTE-ACS patients, without an indication for oral anticoagulation, treated across Romania. Read More

View Article and Full-Text PDF

Antithrombotic Management of Elderly Patients With Coronary Artery Disease.

JACC Cardiovasc Interv 2021 Apr;14(7):723-738

Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, USA. Electronic address:

Antithrombotic therapy represents the mainstay of treatment in patients with coronary artery disease (CAD), including elderly patients who are at increased risk for ischemic recurrences. However, the elderly population is also more vulnerable to bleeding complications. Numerous mechanisms, including abnormalities in the vasculature, thrombogenicity, comorbidities, and altered drug response, contribute to both increased thrombotic and bleeding risk. Read More

View Article and Full-Text PDF

Intolerance to Multiple P2Y12 Inhibitors Following Percutaneous Coronary Intervention.

Cureus 2021 Feb 26;13(2):e13574. Epub 2021 Feb 26.

Cardiovascular Disease, Allegheny Health Network, Pittsburgh, USA.

Dual antiplatelet therapy (DAPT), defined as administration of a P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin, is recommended after percutaneous coronary intervention. We describe a case of a 50-year-old gentleman with intolerance to the three previously mentioned P2Y12 inhibitors following the placement of a drug-eluting stent to the left anterior descending artery. To our knowledge, based on a thorough review of the literature, this is the second case reporting a similar medical dilemma. Read More

View Article and Full-Text PDF
February 2021

Evaluation of safety of switching between oral P2Y12 inhibitors: a descriptive study.

Am J Cardiovasc Dis 2021 15;11(1):108-114. Epub 2021 Feb 15.

Department of Pharmacy Services, Brigham and Women's Hospital Boston, MA, USA.

Purpose: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is recommended for patients with acute coronary syndrome and after percutaneous coronary intervention with stenting in stable coronary artery disease to help prevent further thromboembolic events. However, there is limited guidance on appropriate strategies for switching between oral P2Y12 inhibitors. The aim of this study was to evaluate safety of switching modalities at our institution and compare them to the recently published expert consensus recommendations. Read More

View Article and Full-Text PDF
February 2021

Prasugrel and Ticagrelor in Patients with Drug-Eluting Stents and Kidney Failure.

Clin J Am Soc Nephrol 2021 Apr 2. Epub 2021 Apr 2.

Renal Division, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Background And Objectives: Prasugrel and ticagrelor have superior efficacy compared with clopidogrel in moderate CKD but have not been studied in kidney failure. The study objective is to determine the effectiveness and safety of prasugrel and ticagrelor in kidney failure.

Design, Setting, Participants, & Measurements: This retrospective cohort study used United States Renal Data System data from 2012 to 2015. Read More

View Article and Full-Text PDF

Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus.

Int J Mol Sci 2021 Mar 17;22(6). Epub 2021 Mar 17.

Department of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland.

Blood platelets' adenosine receptors (AR) are considered to be a new target for the anti-platelet therapy. This idea is based on in vitro studies which show that signaling mediated by these receptors leads to a decreased platelet response to activating stimuli. In vivo evidence for the antithrombotic activity of AR agonists published to date were limited, however, to the usage of relatively high doses given in bolus. Read More

View Article and Full-Text PDF

Evaluation of a Real-World In-Hospital Antiplatelet-Switching Strategy Following Coronary Interventions: The SWITCH Study.

J Invasive Cardiol 2021 Apr;33(4):E263-E268

UMass Memorial Medical Center, Cardiovascular Medicine, 55 Lake Avenue North, Worcester, MA 01655 USA.

Background: Antiplatelet therapy is paramount to reduce the risk of coronary stent thrombosis after percutaneous coronary intervention (PCI). Newer agents are reliable and have a fast onset of action, but have significantly higher cost, leading to compliance concerns. We adopted and evaluated an acute agent-switching strategy, using prasugrel or ticagrelor for rapid and reliable periprocedural antiplatelet action, followed by a switch to generic clopidogrel. Read More

View Article and Full-Text PDF

Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.

Zeyi Zhang Ou Chen

J Cardiovasc Pharmacol 2021 May;77(5):536-543

School of Nursing and Rehabilitation, Shandong University, Jinan, China.

Abstract: Dual antiplatelet treatment, consisting of aspirin and P2Y12 inhibitors, is essential for diabetes mellitus (DM) patients who have undergone percutaneous coronary intervention (PCI). This meta-analysis investigated whether ticagrelor, a novel P2Y12 inhibitor, was superior to clopidogrel and prasugrel in efficacy and safety for DM patients undergoing PCI. PubMed, the Cochrane Library and Google Scholar were searched for randomized controlled trials in which ticagrelor was administered. Read More

View Article and Full-Text PDF

Improving Outcomes in Cardiovascular Diseases: A Review on Vorapaxar.

Cardiol Rev 2021 Mar 19. Epub 2021 Mar 19.

Mayo Clinic, Rochester, MN Division of Cardiology, University of Pittsburgh Medical Centre Heart and Vascular Institute, Pittsburgh, PA Garden City Hospital, Garden City, MI Sinai Hospital of Baltimore, Baltimore, MD Johns Hopkins University School of Medicine, Baltimore, MD.

Antiplatelet agents are the standard of practice in the management of atherosclerosis and acute coronary syndrome (ACS). In contrast to the available antiplatelet agents, vorapaxar represents a novel mechanism of action. It is an antagonist of the platelet protease-activated receptor-1 (PAR-1) and inhibits thrombin-induced and thrombin receptor agonist peptide (TRAP)- induced platelet aggregation. Read More

View Article and Full-Text PDF

P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor.

Heart 2021 Mar 23. Epub 2021 Mar 23.

Department of Cardiology, Korea University Guro Hospital, Seoul, Korea (the Republic of).

Objective: To compare P2Y12 inhibitor monotherapy after 3-month dual antiplatelet therapy (DAPT) with 12-month DAPT according to the type of P2Y12 inhibitor in patients undergoing percutaneous coronary intervention (PCI).

Methods: The Smart Angioplasty Research Team: Comparison Between P2Y12 Antagonist Monotherapy vs Dual Antiplatelet Therapy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents (SMART-CHOICE) randomised trial compared 3-month DAPT followed by P2Y12 inhibitor monotherapy with 12-month DAPT. In this trial, 2993 patients undergoing successful PCI with drug-eluting stent were enrolled in Korea. Read More

View Article and Full-Text PDF

Single antiplatelet therapy with use of prasugrel in patients undergoing percutaneous coronary intervention.

Catheter Cardiovasc Interv 2021 Mar 22. Epub 2021 Mar 22.

Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland.

Objectives: We aimed to assess the ischemic and bleeding risks of single antiplatelet therapy (SAPT) with prasugrel compared with standard dual antiplatelet therapy (DAPT) (aspirin plus clopidogrel for 1 year) in patients with chronic coronary syndrome (CCS) treated with new generation drug-eluting stents (DES).

Background: To date, data on SAPT with potent P2Y12 inhibitors in the absence of aspirin immediately after PCI are limited.

Methods: Between January 2009 and November 2019, all CCS patients undergoing percutaneous coronary intervention (PCI) enrolled to the Bern PCI registry were considered for analysis. Read More

View Article and Full-Text PDF

Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: a meta-analysis.

Vascul Pharmacol 2021 Mar 19:106858. Epub 2021 Mar 19.

Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria; Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CEPT), Medical University of Warsaw, Warsaw, Poland. Electronic address:

Introduction: The ideal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) is still unknown. In this meta-analysis, we aimed to compare very short-term (1-3 months), short-term (6 months), standard-term (12 months) and long-term (>12 months) DAPT durations for efficacy and safety.

Methods: Overall DAPT comparisons were classified as "any shorter-term"/"any longer-term" DAPT. Read More

View Article and Full-Text PDF

Characteristics and clinical outcomes of patients with de-escalation from prasugrel to clopidogrel after acute myocardial infarction - Insights from the prospective Japan Acute Myocardial Infarction Registry (JAMIR).

J Cardiol 2021 Mar 18. Epub 2021 Mar 18.

Department of Cardiovascular Medicine, Tohoku University, 1-1, Seiryomachi, Aoba-ku, Sendai, Sendai 980-8574, Japan. Electronic address:

Background: De-escalation of P2Y12 inhibitor may occur for various clinical reasons in patients with acute myocardial infarction (AMI). We aimed to assess the characteristics and outcomes of patients who underwent a de-escalation strategy in real-world clinical practice.

Methods And Results: We studied 2604 AMI patients initially treated with prasugrel using the Japan Acute Myocardial Infarction Registry (JAMIR) database. Read More

View Article and Full-Text PDF

Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y Inhibitor Therapy: A Meta-Analysis.

JACC Cardiovasc Interv 2021 Apr 17;14(7):739-750. Epub 2021 Mar 17.

Peter Munk Cardiac Centre and Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Ontario, Canada.

Objectives: The aim of this study was to examine the effect of CYP2C19 genotype on clinical outcomes in patients with coronary artery disease (CAD) who predominantly underwent percutaneous coronary intervention (PCI), comparing those treated with ticagrelor or prasugrel versus clopidogrel.

Background: The effect of CYP2C19 genotype on treatment outcomes with ticagrelor or prasugrel compared with clopidogrel is unclear.

Methods: Databases through February 19, 2020, were searched for studies reporting the effect of CYP2C19 genotype on ischemic outcomes during ticagrelor or prasugrel versus clopidogrel treatment. Read More

View Article and Full-Text PDF

Ticagrelor versus prasugrel for PCI-managed myocardial infarction: the battle of the giants continues.

Robert F Storey

Heart 2021 Mar 19. Epub 2021 Mar 19.

Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK

View Article and Full-Text PDF

Potent P2Y12 inhibitors versus Clopidogrel in elderly patients with acute coronary syndrome: Systematic review and meta-analysis.

Am Heart J 2021 Mar 15;237:34-44. Epub 2021 Mar 15.

Division of Cardiovascular Medicine, New York University Grossman School of Medicine, NY.

Background: Potent P2Y12 inhibitors reduce cardiovascular events but increase bleeding in patients presenting with acute coronary syndrome (ACS). Elderly patients are at increased risk of bleeding and whether the benefit-risk ratio of potent P2Y12 inhibitors remains favorable is not known.

Objectives: To investigate the efficacy and safety of potent P2Y12 inhibitors versus clopidogrel in elderly patients with ACS. Read More

View Article and Full-Text PDF